A Phase 2 Multicenter Randomized Double-blind Placebo-controlled Study to Evaluate the Safety Tolerability Pharmacokinetics and Efficacy of TTI-101 in Participants with Idiopathic Pulmonary Fibrosis

Brief description of study

A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TTI-101 in Participants with Idiopathic Pulmonary Fibrosis


Clinical Study Identifier: s23-00399
ClinicalTrials.gov Identifier: NCT05671835
Principal Investigator: Rany Condos.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.